HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Electronic Letters to:

Articles: Rosemarie G. Ramos and Kenneth Olden The Prevalence of Metabolic Syndrome Among US Women of Childbearing Age Am J Public Health 2008; 98: 1122-1127 [Abstract] [Full text] [PDF]

eLetters: Submit a response to this article

Electronic letters published:

Pre-Metabolic and Metabolic Syndrome Are Based on Paramount Inherited Mitochondrial Cytopathy

Sergio Stagnaro   (4 June 2008)

Pre-Metabolic and Metabolic Syndrome Are Based on Paramount Inherited Mitochondrial Cytopathy 4 June 2008
Sergio Stagnaro, Researcher in Biophysical Semeiotics Riva Trigoso (Genova) Italy Biophysical Semeiotics Research Laboratory Send letter to journal: Re: Pre-Metabolic and Metabolic Syndrome Are Based on Paramount Inherited Mitochondrial Cytopathy dottsregio{at}semeioticabiofisica.it Sergio Stagnaro	Editors, In primary prevention as well as early bedside diagnosis of metabolic syndrome, physicians have necessarily to know of Biophysical-Semeiotic Constitutions, the fundamental ground of Single Patient Based Medicine (1, 2). They truly exist and are based on inherited mitochondrial functional cytopathy, which I discovered and described for the first time about 30 years ago, and termed Congenital Acidosic Enzyme Metabolic Histangiopathy (1- 15). Notoriously, metabolic syndrome (i.e., all its components) is preceded by the related biophysical-semeiotic constitutions, their corresponding inherited real risk, and then by pre-metabolic syndrome (see www.semeioticabiofisica.it and the linked microangiologia) (2-4). Generally, metabolic syndrome is characterized by a group of "so- called" metabolic risk factors in one person: A) abdominal obesity (excessive fat tissue in and around the abdomen); B) atherogenic dyslipidemia (blood fat disorders - high triglycerides, low HDL cholesterol, and high LDL cholesterol - that foster plaque buildup in artery walls); C) elevated blood pressure; D) insulin resistance or glucose intolerance (the body can't properly use insulin or blood sugar); E) prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor-1 in the blood); and F) proinflammatory state (e.g., elevated C-reactive protein in the blood). As I referred to previously and also recently (15), all of these components of metabolic syndrome may occur exclusively in individuals affected by Congenital Acidosic Enzyme Metabolic Histangiopathy as well as by either "some" or all biophysical-semeiotic constitutions. In a few words, not all patients with metabolic syndrome are equal! Interestingly, important data gathered at the bedside with the aid of Biophysical Semeiotics has proven to be reliable in my long, well-established clinical experience. In fact, they highlight intriguing aspects of metabolic syndrome that until now have remained unexplained: for instance, only 50% of people with this syndrome have impairment of glucose metabolism, e.g., type 2 diabetes. In fact, no authors anywhere in the world have been able to provide a full explanation for what accounts for the fact that glucose metabolism is altered in only about one- half of patients with metabolic syndrome. In addition, CAD primary prevention has to be performed exclusively in those patients affected by inherited CAD real risk, based on coronary micorcirculatory remodelling, wherein newborn-pathological, type I, subtype b, aspecific, endoarteriolar blocking devices play a central role (8, 9, 16). References 1) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico- Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Travel Factory, Roma, 2004. http://www.travelfactory.it. 2) Stagnaro S., Stagnaro-Neri M., Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Ed. Travel Factory, Roma, 2005. 3) Stagnaro SergioBiophysical Semeiotic Constitutions, Genomics, and Cardio-Vascular Diseases. BMC Cardiovascular Disorders http://www.biomedcentral.com/1471-2261/4/20/comments#95454 2004. 4) Stagnaro Sergio. Single Patient Based Medicine: its paramount role in Future Medicine. Public Library of Science. http://medicine.plosjournals.org/perlserv/?request=read-response 2005. 5) Stagnaro Sergio. Bedside diagnosing diabetic and dyslipidaemic constitutions and diabetes real risk. 2 October 2006, Brit. Col. Med. Journal. http://www.cmaj.ca/cgi/eletters/175/7/733 2006. 6) Stagnaro Sergio. Hypertensive Constitution accounts for the existence of diabetics with and without Hypertension. Cardiovascular Diabetology 2006, 5:19 doi:10.1186/1475-2840-5-19 2006. 7) Stagnaro Sergio. Biophysical-Semeiotic Diabetic "and" Dyslipidaemic Constitutions and Primary Prevention. Annals of Family Medicine http://www.annfammed.org/cgi/eletters/4/5/427 2006. 8) Stagnaro Sergio. Newborn-pathological Endoarteriolar Blocking Devices in Diabetic and Dislipidaemic Constitution and Diabetes Primary Prevention. The Lancet. March 06 2007 http://www.thelancet.com/journals/lancet/article/PIIS0140673607603316/comments?action=view&totalComments=1. 9) Stagnaro Sergio. New bedside way in Reducing mortality in diabetic men and women. 21 June 2007. http://www.annals.org/cgi/eletters/0000605- 200708070-00167v1. 10) Stagnaro Sergio. Teoria Patogenetica Unificata, 2006, Ed. Travel Factory, Roma. 2006 11) Stagnaro S. Pivotal role of Biophysical Semeiotic Constitutions in Primary Prevention. Cardiovascular Diabetology, 2:1, http://www.cardiab.com/content/2/1/13/comments#5753 2003. 12) Stagnaro S., Istangiopatia Congenita Acidosica Enzimo-Metabolica condizione necessaria non sufficiente della oncogenesi. XI Congr. Naz. Soc. It. di Microangiologia e Microcircolaz. Abstracts, pg 38, 28 Settembre-1 Ottobre, 1983, Bellagio. 13) Stagnaro S., Istangiopatia Congenita Acidosica Enzimo-Metabolica. X Congr. Naz. Soc. It. di Microangiologia e Microcircolazione. Atti, 61. 6-7 Novembre, 1981. Siena. 14) Stagnaro S., Istangiopatia Congenita Acidosica Enzimo-Metabolica. Gazz Med. It. - Asch. Sci, Med. 144, 423, 1985. 15) Stagnaro Sergio. Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes. Eur J Clin Nutr. 2007 Feb 7. 16) Stagnaro Sergio. Role of Coronary Endoarterial Blocking Devices in Myocardial Preconditioning - c007i. Lecture, V Virtual International Congress of Cardiology. http://www.fac.org.ar/qcvc/llave/c007i/stagnaros.php 2007.